Prognostic Significance of HER2 Expression Changes Following Neoadjuvant Chemotherapy in Saudi Patients With Locally Advanced Breast Cancer
| Autor: | Abdurrahman Aldiab, Ammar C. Al-Rikabi, Khalid Alsaleh, Nashwa Abd El-Aziz, Tareq Salah, Sufia Husain, Maria Arafah |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Saudi Arabia Estrogen receptor Antineoplastic Agents Breast Neoplasms Disease-Free Survival Young Adult 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Progesterone receptor medicine Carcinoma Humans skin and connective tissue diseases Aged Retrospective Studies Chemotherapy medicine.diagnostic_test business.industry Middle Aged Prognosis medicine.disease Neoadjuvant Therapy Survival Rate 030104 developmental biology Receptors Estrogen Chemotherapy Adjuvant 030220 oncology & carcinogenesis Immunohistochemistry Female Histopathology Receptors Progesterone business Fluorescence in situ hybridization |
| Zdroj: | Clinical Breast Cancer. 21:e362-e367 |
| ISSN: | 1526-8209 |
| Popis: | Progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) significantly influence disease prognosis and therapeutic response in patients with breast cancer. Neoadjuvant chemotherapy (NACT) can change the receptor status, affecting the disease characteristics.A retrospective chart review was carried out at a single tertiary care hospital in Riyadh, Kingdom of Saudi Arabia, from December 2008 to December 2014, where 91 adult female patients diagnosed with locally advanced breast cancer planning to receive NACT were included. Original pathology and surgical histopathology reports were assessed, and patients were followed up to recurrence, death, or until December 2019. An expression for the ER, PR, and HER2 was carried out in pre and post NACT specimens by an experienced pathologist, and all HER2 with 2+ immunohistochemistry was sent for fluorescence in situ hybridization as per American Society of Clinical Oncology guidelines.ER pre- and postoperatively changed from positive to negative in 17.6% of patients and from negative to positive in 1.1% of patients (P .001). ER status remained stable in 81.3% of patients. PR changed from positive to negative in 13.2% of patients, and from negative to positive in 3.3% of patients (P .001), whereas it remained stable in 83.5% of patients. HER2 changed from positive to negative in 11% of patients, and from negative to positive in 5.5% of patients (P .001), and it remained stable in 83.5% of patients. No significant association was found between overall survival and disease-free-survival with HER2 expression change.NACT can induce changes in the ER, PR, and HER2 status, which should be evaluated post-NACT to choose the optimal treatment regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect